Gaetano Rocco: Difference between revisions

From Top Italian Scientists Wiki
No edit summary
Line 111: Line 111:
# An open label trial of afatinib in treatment-naïve (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s). Role: Surgical Investigator.
# An open label trial of afatinib in treatment-naïve (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s). Role: Surgical Investigator.
# BR-31 A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER.<ref name="CTGov" /> Role: Principal Investigator.
# BR-31 A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER.<ref name="CTGov" /> Role: Principal Investigator.
== Honors and awards ==
* 2006: Silver Medal “Aesculapius” of the Italian Minister of Health for Professional Achievements.
* 2011: Alumnus d'Honore from Hopital Marie-Lannelongue, Universite Sud, Paris, France.
* 2016: Listed in “Top Italian Scientists” website.
* 2022: Honorary Membership (Life Achievement Award) European Society of Thoracic Surgeons.


== References ==
== References ==
<references/>
<references/>

Revision as of 16:26, 9 March 2023

Gaetano Rocco (born July 15, 1960, Milan, Italy). He is Director, Chest Wall Surgery Program and Attending Surgeon at the MSKCC, New York, NY[1].

Gaetano Rocco
Born
July 15, 1960, Milan, Italy
Nationality
Italian
Education
MD, University of Milan, Italy
Fields
Thoracic Surgery, Translational medicine, Clinical guidelines, Minimally invasive thoracic surgery
Institutions
Director, Chest Wall Surgery Program, MSKCC, New York, NY
Attending Surgeon, MSKCC, New York, NY
Notes
Top Italian Scientist in Clinical Sciences [2]

Education and career

Academic Degree

  • 1985: MD, University of Milan, Italy.

Post-doctoral training =

  • 1984, 1986, 1987-1988: Research Fellow in Surgical Pathology, Stritch School of Medicine, Loyola University, Chicago, IL.
  • 1985-1990: Resident, General Surgery, University of Milan Hospitals, Milan, Italy.
  • 1990-1995: Resident, Thoracic Surgery, University of Milan Hospitals, Milan, Italy.
  • 1995: Visiting Resident, Section of General Thoracic Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN.
  • 1996-1997: Clinical Fellow in Advanced General Thoracic Surgery, Section of General Thoracic Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN.
  • 1999: Fellowship in Laparoscopic Surgery, University of Strasbourg, France, on behalf of the European Institute of Telesurgery (EITS), Strasbourg, France.
  • 2000: Research Fellow, British Mesothelioma Group, British Lung Volume Reduction Group.
  • 2003: Research Fellow, MRC LU-22.

Career

Academic positions

  • 1992: Professor of Surgery, E. Morelli Regional Hospital, Nursing School, Sondalo, Italy.
  • 1993-1999: Professor of Thoracic Surgery, E. Morelli Regional Hospital, Nursing School, Sondalo, Italy.
  • 2000-2004: Hon. Senior Clinical Lecturer, Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield Teaching Hospitals, Sheffield, UK.
  • 2004-2006: Faculty, European School for Cardiothoracic Surgery, Bergamo level II.
  • 2011-2018: Professor of Thoracic Surgery, University of Naples, Italy.
  • 2011-2018: Professor of Cardiothoracic Surgery, University of Naples, Italy.
  • 2012-2018: Professor of Thoracic Surgery University of Bari, Italy.

Hospital positions

  • 1988-1999: Staff Thoracic Surgeon, E. Morelli Regional Hospital, Sondalo, Italy.
  • 2000-2004: Consultant Thoracic Surgeon, Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield Teaching Hospitals, Sheffield, UK.
  • 2004-2018: Chief, Division of Thoracic Surgery, National Cancer Institute, Pascale Foundation, Naples, Italy.
  • 2008-2018: Head, Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, Naples, Italy,
  • 2018-Present: Attending Surgeon, MSKCC, New York, NY.
  • 2021-Present: Director, Chest Wall Surgery Program, MSKCC, New York, NY

Other Employment

  • 1986-1987: Medical Officer, Italian Army.

Research

Clinical Trials

  1. ITACA EudraCT n. 2008-001764-36 “Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer” Start date: 2008 – Institutional co-Principal Investigator.
  2. MILES-3 Cisplatin in Combination With Gemcitabine for Elderly Patients With Stage IIIB-IV Non Small Cell Lung. Role: Surgical Investigator.[3]
  3. MILES-4 Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Elderly Patients With Advanced Nonsquamous Lung Cancer. Role: Surgical Investigator.[3]
  4. PETRA. Study of Metabolic Response measured with PET/CT after the first cycle of chemotherapy in patients with Advanced Non Small Cell Lung Cancer. Role: Surgical Investigator.
  5. ERACLE GOIM Protocol 2903. Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance: Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer. Role: Surgical Investigator.[3]
  6. ARQ197. A phase 3, randomized, double-blinded, placebo controlled, study of ARQ197 plus erlotinib versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic non-squamous non small cell lung cancer (NSCLC). Role: Surgical Investigator.[3]
  7. INSPIRE. A randomized, multicenter, open-label phase 3 study of pemetrexed-cisplatin chemotherapy plus IMC-11F8 versus pemetrexed-cisplatin chemotherapy alone in the first line treatment of patients with non squamous stage IIIB or IV Non-Small Cell Lung Cancer (IMCL CP11-0805; INSPIRE). Role: Surgical Investigator.[3]
  8. SQUIRE. A randomized, multicenter, open-label phase 3 study of gemcitabine-cisplatin chemotherapy plus IMC-11F8 versus gemcitabine-cisplatin chemotherapy alone in the first line treatment of patients with squamous stade IIIB or IV Non-Small Cell Lung Cancer (IMCL CP11-0806;SQUIRE). Role: Surgical Investigator.[3]
  9. Phase 2, open label single arm study of the efficacy and safety of PF-02341066 in patients with advanced non-small cell lung cancer harbouring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus. Role: Surgical Investigator
  10. Phase 3, randomized open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced non-small cell lung cancer harbouring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus. Role: Surgical Investigator.
  11. NCIC CTG BR.26. A double blind placebo controlled trial of PF-804 in patients with incurable stage IIIB/IV NSCLC after failure of standard therapy for advanced or metastatic disease (NCIC CTG BR.26). Role: Surgical Investigator.[3]
  12. LUX-Lung 8 - A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy. Role: Surgical Investigator.[3]
  13. ICARUS. A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Responded to Gefitinib in 1st Line and Progressed After 2nd Line Chemotherapy (Studio ICARUS). Role: Surgical Investigator.[3]
  14. AVALL MO22097. An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy regimen (AVALL - Roche). Role: Surgical Investigator.
  15. ASSESS. A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing: The ASSESS Study (Astra Zeneca). Role: Surgical Investigator.[3]
  16. BASALT 2. A Dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) of squamous histology (BASALT 2 – Novartis). Role: Surgical Investigator.[3]
  17. BASALT 3. A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer (BASALT 3 - Novartis). Role: Surgical Investigator.[3]
  18. Phase I Study of single agent MK-3475 in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung carcinoma (MERK). Role: Surgical Investigator
  19. Observational study “E-Lung”. Lung cancer: from patient’s needs, the answers from oncology. Role: Surgical Investigator.
  20. ARCHER Study A7471009: a randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy (ARCHER 1050 – Pfizer). Role: Surgical Investigator.[3]
  21. SELECT-1. A phase III, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of selumetinib (AZD6244) in combination with docetaxel in patients receiving second line treatment for KRAS mutation-positive locally advanced or metastatic non small cell lung cancer (stage IIIB – IV) (SELECT-1 – Astra Zeneca). Role: Surgical Investigator.[3]
  22. An open label trial of afatinib in treatment-naïve (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s). Role: Surgical Investigator.
  23. BR-31 A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER.[3] Role: Principal Investigator.

Honors and awards

  • 2006: Silver Medal “Aesculapius” of the Italian Minister of Health for Professional Achievements.
  • 2011: Alumnus d'Honore from Hopital Marie-Lannelongue, Universite Sud, Paris, France.
  • 2016: Listed in “Top Italian Scientists” website.
  • 2022: Honorary Membership (Life Achievement Award) European Society of Thoracic Surgeons.


References

  1. ↑ Gaetano Rocco - Memorial Sloan Kettering Cancer Center
  2. ↑ Gaetano Rocco - Top Italian Scientist in Clinical Sciences
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 Home - ClinicalTrials.gov
Retrieved from "https://en.wiki.topitalianscientists.org/index.php?title=Gaetano_Rocco&oldid=963"